Home > Insider Trading > Filing (0000899243-18-029132)

Filing Details

Accession Number:: 0000899243-18-029132
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-11-16 16:35:22
Reporting Period:: 2018-11-14

Accepted Time:: 2018-11-16 16:35:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1325879	Aveo Pharmaceuticals Inc	AVEO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1239241	B Anthony Evnin	C/O Aveo Pharmaceuticals, Inc. One Broadway, 14Th Floor Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-11-14	325,139	$1.90	821,929	No	4	S	Indirect	By Funds
Common Stock	Disposition	2018-11-15	670,894	$1.86	151,035	No	4	S	Indirect	By Funds
Common Stock	Disposition	2018-11-16	151,035	$1.82	0	No	4	S	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Funds
No	4	S	Indirect	By Funds
No	4	S	Indirect	By Funds

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	418,414	Direct

Footnotes

Consists of (a) 58,519 shares of common stock sold by Venrock Associates, or VA, (b) 260,087 shares of common stock sold by Venrock Associates III, L.P., or VA III, (c) 6,502 shares of common stock sold by Venrock Entrepreneurs Fund III, L.P., or VEF III, and (d) 31 shares of common stock sold by VEF Management III, LLC, or VEFM III.
The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.89 to $1.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Dr. Evnin is a General Partner of VA. Venrock Management III, LLC, or VM III, is the sole General Partner of VA III. VEFM III, is the sole General Partner of VEF III. Dr. Evnin is a Member of VM III and VEFM III. Dr. Evnin expressly disclaims beneficial ownership over all shares held by or on behalf of VA, VA III, VEF III, VM III, and VEFM III, except to the extent of his indirect pecuniary interest therein.
Consists of (a) 120,749 shares of common stock sold by VA, (b) 536,665 shares of common stock sold by VA III, (c) 13,416 shares of common stock sold by VEF III, and (d) 64 shares of common stock sold by VEFM III.
The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.85 to $1.875, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Consists of (a) 27,184 shares of common stock sold by VA, (b) 120,817 shares of common stock sold by VA III, (c) 3,020 shares of common stock sold by VEF III, and (d) 14 shares of common stock sold by VEFM III.
The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.785 to $1.85, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
None of the shares held directly by Dr. Evnin were sold in these transactions.